APTX News and Press, Aptinyx Inc. From 03/23/22

Aptinyx press release (NASDAQ:APTX): Q4 GAAP EPS of -$0.29 beats by $0.05. Cash and cash equivalents were $106.1 million at December 31, 2021. For further details see: Aptinyx GAAP EPS of -$0.29 beats by $0.05

Data readouts from Phase 2b studies of NYX-2925 in painful DPN and fibromyalgia expected in April 2022 and early to mid 3Q 2022, respectively Ongoing Phase 2 study in cognitive impairment expected to read out in late 2022 or 1Q 2023 Initiated Phase 2b study of NYX-783 ...

APTX, FSM, FUL, HTHT, KBH, NAVB, OLLI, PHUN, SCS, SIEN, SOL, TCOM For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Wednesday's close

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 23, 2022 at 5:00 p.m. ET...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in the Neuropsychiatry Pan...

Results from the Phase 2b study are expected in early to mid 3Q 2022 Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollm...

Live webcast today beginning at 10:00 a.m. ET Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will host a virtual portfolio review event today beginning at 10...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat...

Leading experts in neuroscience will provide guidance to support the advancement of Aptinyx’s novel NMDA receptor modulation platform and pipeline Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treat...